OncoC4 dosed first participant in Phase 1/2 trial of ONC-841 for Alzheimer's disease at Xuanwu Hospital, China, following NMPA clearance. ONC-841 is world's first anti-SIGLEC 10 antibody.
Expert Consensus on Elderly Gallstone Treatment Released
The 2026 Expert Consensus on Diagnosis and Treatment of Gallstones in the Elderly was released, providing guidelines for standardized care of elderly patients with gallstones in China.
Eisai China and Xuanwu Hospital form strategic partnership
Eisai China and Xuanwu Hospital signed a strategic cooperation agreement, focusing on scientific research, talent cultivation, and academic exchange in the pharmaceutical field.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.
Get full access to view complete information
1 - 13 of 13
Get full access to view complete information
Frequently Asked Questions Regarding Capital University Of Medical Sciences
Company Overview
-
Founded
Higher Education
Industry
China
Location
364,178,347
Ranking
400 employees
Size
Similar Companies
Get full access to view complete information
Frequently Asked Questions Regarding Capital University Of Medical Sciences
Start your journey today
Start with the platform — or start with a conversation
Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.